Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-World Ustekinumab for Plaque Psoriasis in Chinese Patients ≥6 Years
ChiCTR2500115383Phase 4Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ustekinumab in plaque psoriasis, sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: PASI 75 at primary assessment timepoint. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
ustekinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on ChiCTR2500115383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500115383.